(Shanghai, compiled reports) GLP-1 drugs from US drugmaker Pfizer and China’s Innovent Biologics will be covered by China’s national health insurance scheme from 1 January next year for the treatment of conditions including type 2 diabetes and obesity, according to the latest official lists of drugs covered by basic health insurance and innovative medicines. The move puts fresh competitive pressure on Danish drugmaker Novo Nordisk.
According to Reuters and The Paper, the two GLP-1 drugs being added to the scheme are Pfizer’s ecnoglutide and Innovent’s mazdutide. Both are GLP-1 receptor agonists, which mimic a gut hormone to suppress appetite and regulate blood sugar levels in people with diabetes.
Pfizer acquired the rights to ecnoglutide through a licensing deal with Sciwind Biosciences, a Chinese innovative drug developer headquartered in Hangzhou.
The International Diabetes Federation estimates that China has the world’s largest adult population with diabetes. Similar drugs from Denmark’s Novo Nordisk, US drugmaker Eli Lilly and Guangzhou Yinnuo Pharma are already covered by China’s national health insurance scheme.
Inclusion on the reimbursement list makes these drugs affordable to more Chinese patients, but growth in sales volumes often comes with price cuts.
China’s National Healthcare Security Administration said 107 drugs had been added to the basic health insurance reimbursement list, including a record 51 Class 1 new drugs.
Other treatments being added to the reimbursement list include two Eli Lilly drugs for ulcerative colitis and Crohn’s disease, as well as a CAR-T therapy from JW Therapeutics.
JW Therapeutics’ product will become the first CAR-T therapy covered by China’s national health insurance scheme. The cancer treatment modifies patients’ immune cells so they can recognise and kill cancer cells.